Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – Results from a non-interventional study

Masoli, 2004, Global Initiative for Asthma (GINA) Program, The global burden of asthma: executive summary of the GINA Dissemination Committee report, Allergy, 59, 469, 10.1111/j.1398-9995.2004.00526.x GINA, 2016 Scotland, 2014 Bundesärztekammer (BÄK), 2013 van Noord, 1999, Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma, Thorax, 54, 207, 10.1136/thx.54.3.207 O'Byrne, 2001, Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial, Am. J. Respir. Crit. Care Med., 164, 1392, 10.1164/ajrccm.164.8.2104102 Pauwels, 1997, Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group, N. Engl. J. Med., 337, 1405, 10.1056/NEJM199711133372001 Woolcock, 1996, Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids, Am. J. Respir. Crit. Care Med., 153, 1481, 10.1164/ajrccm.153.5.8630590 Greening, 1994, Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid, Lancet, 344, 219, 10.1016/S0140-6736(94)92996-3 Delea, 2008, Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma, Clin. Ther., 30, 560, 10.1016/j.clinthera.2008.03.011 Stoloff, 2004, Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies, J. Allergy Clin. Immunol., 113, 245, 10.1016/j.jaci.2003.10.011 Cates, 2014, Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews, Cochrane Database Syst. Rev., 2, Cd010314 Pearlman, 2013, Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma, Clin. Ther., 35, 950, 10.1016/j.clinthera.2013.05.012 Pertseva, 2013, Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial, Curr. Med. Res. Opin., 29, 1357, 10.1185/03007995.2013.825592 Corren, 2013, Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma, Respir. Med., 107, 180, 10.1016/j.rmed.2012.10.025 Nathan, 2012, Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial, BMC Pulm. Med., 12, 67, 10.1186/1471-2466-12-67 Bodzenta-Lukaszyk, 2011, Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler, Respir. Med., 105, 674, 10.1016/j.rmed.2010.11.011 Bodzenta-Lukaszyk, 2011, Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study, BMC Pulm. Med., 11, 28, 10.1186/1471-2466-11-28 Bodzenta-Lukaszyk, 2012, Kombinationstherapie mit Fluticason/Formoterol in einem Dosieraerosol hat vergleichbare Wirksamkeit wie die freie Konbination Fluticason und Formoterol, Pneumologie, 66, 29 Mansur, 2013, Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma, J. Aerosol Med. Pulm. Drug Deliv., 26, 190, 10.1089/jamp.2012.0977 Bodzenta-Lukaszyk, 2012, Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety, J. Asthma, 49, 1060, 10.3109/02770903.2012.719253 Cazzoletti, 2007, Asthma control in Europe: a real-world evaluation based on an international population-based study, J. Allergy Clin. Immunol., 120, 1360, 10.1016/j.jaci.2007.09.019 Demoly, 2010, Update on asthma control in five European countries: results of a 2008 survey, Eur. Respir. Rev., 19, 150, 10.1183/09059180.00002110 Saturni, 2014, Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view, Pulm. Pharmacol. Ther., 27, 129, 10.1016/j.pupt.2014.01.005 Price, 2015, Real-world research and its importance in respiratory medicine, Breathe (Sheff), 11, 26, 10.1183/20734735.015414 flutiform® summary of product characteristics (http://www.medicines.ie; Accessed March 2016). Nathan, 2004, Development of the asthma control test: a survey for assessing asthma control, J. Allergy Clin. Immunol., 113, 59, 10.1016/j.jaci.2003.09.008 Juniper, 2005, Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older, Health Qual. Life Outcomes, 3, 58, 10.1186/1477-7525-3-58 Schatz, 2009, The minimally important difference of the Asthma Control Test, J. Allergy Clin. Immunol., 124, 10.1016/j.jaci.2009.06.053 Juniper, 1994, Determining a minimal important change in a disease-specific Quality of Life Questionnaire, J. Clin. Epidemiol., 47, 81, 10.1016/0895-4356(94)90036-1 Rogala, 2017, Asthma control in adult patients treated with a combination of inhaled corticosteroids and longacting beta2agonists: a prospective observational study, Pol. Arch. Intern Med., 127, 100 Marceau, 2006, Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma, J. Allergy Clin. Immunol., 118, 574, 10.1016/j.jaci.2006.06.034 Price, 2011, Device type and real-world effectiveness of asthma combination therapy: an observational study, Respir. Med., 105, 1457, 10.1016/j.rmed.2011.04.010 Johal, 2013, Fine particle profile of fluticasone propionate/formoterol fumarate versus other combination products: the diffuse study, Comb. Prod. Ther., 3, 39, 10.1007/s13556-013-0003-9 Bender, 2002, Overcoming barriers to nonadherence in asthma treatment, J. Allergy Clin. Immunol., 109, S554, 10.1067/mai.2002.124570 Papi, 2016, Long-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations, J. Aerosol Med. Pulm. Drug Deliv., 29, 346, 10.1089/jamp.2015.1255 Santanello, 1999, What are minimal important changes for asthma measures in a clinical trial?, Eur. Respir. J., 14, 23, 10.1034/j.1399-3003.1999.14a06.x Jacob, 2016, Healthcare costs and resource utilization of asthma in Germany: a claims data analysis, Eur. J. Health Econ., 17, 195, 10.1007/s10198-015-0671-3 Travers, 2007, External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?, Thorax, 62, 219, 10.1136/thx.2006.066837 Hassen, 2016, Voice evaluation in asthma patients using inhaled corticosteroids, Kulak Burun Bogaz Ihtis. Derg., 26, 101, 10.5606/kbbihtisas.2016.79740 Herland, 2005, How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?, Respir. Med., 99, 11, 10.1016/j.rmed.2004.03.026 Kondla, 2016, Asthma control in patients treated with inhaled corticosteroids and long-acting beta agonists: a population-based analysis in Germany, Respir. Med., 118, 58, 10.1016/j.rmed.2016.07.012 Price, 2014, Asthma control and management in 8,000 european patients: the REcognise asthma and LInk to symptoms and experience (REALISE) survey, NPJ Prim. Care Respir. Med., 24, 14009, 10.1038/npjpcrm.2014.9 Caminati, 2016, g. North East Omalizumab Network study, Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience, BMC Pulm. Med., 16, 128, 10.1186/s12890-016-0290-5 Stallberg, 2015, Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy, Int. J. Clin. Pharmacol. Ther., 53, 447, 10.5414/CP202224 Terzano, 2012, 1-year prospective real life monitoring of asthma control and quality of life in Italy, Respir. Res., 13, 112, 10.1186/1465-9921-13-112 Wechsler, 2011, Impact of race on asthma treatment failures in the asthma clinical research network, Am. J. Respir. Crit. Care Med., 184, 1247, 10.1164/rccm.201103-0514OC Wechsler, 2009, Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial, Lancet, 374, 1754, 10.1016/S0140-6736(09)61492-6